Lisa Deschamps
Director/Board Member at VERONA PHARMA PLC
Net worth: 1 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chris E. Shaw | M | - |
AviadoBio Ltd.
 AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| David Zaccardelli | M | 59 | 4 years | |
| Mahendra Shah | M | 79 | 8 years | |
| Jan-Anders Karlsson | M | 69 |
Reset Pharmaceuticals, Inc.
 Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | - |
| Graeme Fielder | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 4 years |
| James Brady | M | 61 | 2 years | |
| Youn Bok Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Vikas Sinha | M | 60 | 8 years | |
| Philip Taub | M | - |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | - |
| Victoria Stewart | F | - | 5 years | |
| David Ebsworth | M | 69 | 10 years | |
| Ken Cunningham Cunningham | M | 71 | 9 years | |
| Sven Anders Ullman | M | 68 | 9 years | |
| Martin Edwards | M | 68 | 5 years | |
| Nihal Sinha | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Kavita Aggarwal | M | - | 1 years | |
| Michael Austwick | M | 54 | - | |
| Christopher Martin | M | - | 4 years | |
| Do Young Lee | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Mark Hahn | M | 61 | 4 years | |
| Laurence Barker | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Ostra Jewell | F | - | 2 years | |
| Tara Rheault | M | 49 | 5 years | |
| John H. Andreadis | M | - |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | - |
| Timothy J Schlidt | M | - |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | - |
| Caroline Diaz | F | - | 3 years | |
| Christina Ackermann | F | 59 | 1 years | |
| Matthew Casbon | M | - | 2 years | |
| J. Goater | M | 48 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 1 years |
| Ben Harber | M | 47 | - | |
| Matthew McAviney | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Kathleen Rickard | M | 65 | 5 years | |
| Amber Salzman | M | 62 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | - |
| Chris Burggraeve | M | 58 |
The Leonard N Stern School of Business
| 12 years |
| Tim Funnell | M | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ruchi Hazaray | F | - |
The Leonard N Stern School of Business
| 3 years |
| Sean Nolan | M | 56 | 3 years | |
| Michael B. Johannesen | M | - | 3 years | |
| Petra Kaufmann | M | 58 | 3 years | |
| Brian K. Kaspar | M | - | - | |
| Philip Donenberg | M | 63 | 2 years | |
| Claire Poll | F | 57 | 18 years | |
| Frank Verwiel | M | 61 | 3 years | |
| Rishi Gupta | M | 46 | 8 years | |
| Howard Chang | M | - |
The Leonard N Stern School of Business
| 4 years |
| Oliver Hu | M | - |
The Leonard N Stern School of Business
| 4 years |
| Anne Lee | F | - |
The Leonard N Stern School of Business
| 4 years |
| Andrew Lifshitz | M | - |
The Leonard N Stern School of Business
| 4 years |
| Angela Thedinga | F | 42 | 1 years | |
| Ajay Chinni | M | - |
The Leonard N Stern School of Business
| 4 years |
| Grace Kim | F | - |
The Leonard N Stern School of Business
| 3 years |
| Berry Gong | F | - |
The Leonard N Stern School of Business
| 4 years |
| Allen Acosta | M | - |
The Leonard N Stern School of Business
| 4 years |
| Na-Young Park | F | - |
The Leonard N Stern School of Business
| 3 years |
| Cesar Pomarico | M | - |
The Leonard N Stern School of Business
| 4 years |
| Adam Bowie | M | - |
The Leonard N Stern School of Business
| 2 years |
| Vikas Desai | M | - |
The Leonard N Stern School of Business
| 4 years |
| Andrew Eisenson | M | - |
The Leonard N Stern School of Business
| 4 years |
| Darien Cheng | M | - |
The Leonard N Stern School of Business
| 4 years |
| Isabella Zeng | F | - |
The Leonard N Stern School of Business
| 4 years |
| Sashank Parigi | M | - |
The Leonard N Stern School of Business
| 4 years |
| Rakesh Gidwani | M | - |
The Leonard N Stern School of Business
| 3 years |
| Spencer Payne | M | - |
The Leonard N Stern School of Business
| 2 years |
| William Friedrich Patterson | M | - |
The Leonard N Stern School of Business
| 2 years |
| Adria Sai-Halasz | F | - |
The Leonard N Stern School of Business
| 4 years |
| Rahul Hukeri | M | - |
The Leonard N Stern School of Business
| 2 years |
| Adam Fazlibegu | M | - |
The Leonard N Stern School of Business
| 4 years |
| Jason Park | M | - |
The Leonard N Stern School of Business
| 4 years |
| James Tong | M | - |
The Leonard N Stern School of Business
| 4 years |
| Clayton Bryan | M | - |
The Leonard N Stern School of Business
| 2 years |
| Diana Jin | F | - |
The Leonard N Stern School of Business
| 4 years |
| Tomer Kogan | M | - |
The Leonard N Stern School of Business
| 3 years |
| Benjamin Jošar | M | 51 |
The Leonard N Stern School of Business
| 2 years |
| Jared Scott Sender | M | - |
The Leonard N Stern School of Business
| 2 years |
| Nicole Weil | F | - |
The Leonard N Stern School of Business
| 2 years |
| Harry Mateer | M | - |
The Leonard N Stern School of Business
| 4 years |
| Satoshi Tominaga | M | 46 |
The Leonard N Stern School of Business
| 1 years |
| Gunjan K. Banati | F | - |
The Leonard N Stern School of Business
| 1 years |
| Christopher Ellis-Ferrara | M | - |
The Leonard N Stern School of Business
| 1 years |
| Aditya Garg | M | - |
The Leonard N Stern School of Business
| 4 years |
| Gloria Gao | F | - |
The Leonard N Stern School of Business
| 4 years |
| Kevin Gonzalez | M | - |
The Leonard N Stern School of Business
| 4 years |
| Raymond Wong | M | - |
The Leonard N Stern School of Business
| 4 years |
| Erik Woodring | M | - |
The Leonard N Stern School of Business
| 2 years |
| Jay Yang | M | - |
The Leonard N Stern School of Business
| 4 years |
| Cason Kim | M | - |
The Leonard N Stern School of Business
| 3 years |
| Max Mudd | M | - |
The Leonard N Stern School of Business
| 4 years |
| Aman Gherger | M | - |
The Leonard N Stern School of Business
| 2 years |
| Sirisha Kurada | F | - |
The Leonard N Stern School of Business
| 2 years |
| Maxwell Shnaper | M | - |
The Leonard N Stern School of Business
| 4 years |
| Brajesh Mishra | M | - |
The Leonard N Stern School of Business
| 2 years |
| Avisha Thakkar | F | - |
The Leonard N Stern School of Business
| 4 years |
| Rachael Harrison | F | - |
The Leonard N Stern School of Business
| 4 years |
| Jenny Pikman | F | - |
The Leonard N Stern School of Business
| 4 years |
| Ethan Ellison | M | - |
The Leonard N Stern School of Business
| 2 years |
| Austin Clements | M | - |
The Leonard N Stern School of Business
| 2 years |
| Ashley Chang | F | - |
The Leonard N Stern School of Business
| 4 years |
| Arun Manikundalam | M | - |
The Leonard N Stern School of Business
| 3 years |
| Sarah Tan | F | - |
The Leonard N Stern School of Business
| 4 years |
| Jason Lai | M | - |
The Leonard N Stern School of Business
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 68 | 68.00% |
| United Kingdom | 32 | 32.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lisa Deschamps
- Personal Network
